All News

Uncertainty swirls on just how effective policy competition between the EU and UK on these much-needed products will be.

Capital to be invested in company’s AI platform and discovery pipeline.

In this exclusive Q&A with Pharmaceutical Executive, Janice Chang, CEO of TransCelerate BioPharma, provides an inside look into her career journey, her work at the company, how the industry has changed in the last 10 years, as well as her thoughts on where the industry should put its efforts in clinical trials.

A look at the rise of prior authorization certified specialists (PACS)—and their value in improving patient access and outcomes.

Companies hope to accelerate fight against cancer

Strategy includes a layoff of nearly 400 employees.

The UK BioIndustry Association’s Q2 Biotech Financing Report finds improved financing, driven primarily by venture capital investment.

Deal to focus on Poseida’s commitment to cancer cell therapy.

Recent lawsuits are challenging the constitutionality of provisions in the Inflation Reduction Act.

Pandemic preparedness and curbing PBMs among the pending legislation that will have to wait until after summer recess.

Research concludes professional disease education leads to greater treatment adoptions.

Frederique Welgryn, global vice president for women's health, Perrigo, shares insight into the approval of Opill (norgestrel), a progestin-only contraception, in this exclusive Q&A.

Common advice for OA sufferers is joint replacement, but other options are on the horizon.

FDA stresses facility only responsible for 8% of total US hospital consumption for sterile injectable drug market, as well as the need for a reliable drug supply chain.

The agency proposes significant revisions to oversight programs for drugs and medical products.

In this Q&A, Craig Serra, head of commercial solutions and partnerships within the clinical research business unit at Flatiron Health (affiliate of the Roche Group), shares his perspective on clinical research, the role of data, and Flatiron Health’s efforts to that end.

Online HCP community allows HCPs and researchers access to the latest breakthroughs in medicine and life sciences research.

Recent data and commentary offer insights into how biologics vs. small molecule patent protections under the Inflation Reduction Act pricing scenarios is impacting investing in the biotech sector.

The National Alliance of Healthcare Purchaser Coalitions releases resources for employers/health plan purchasers to offer insights on PBMs role in high prescription drug costs.

NORD goes on record that IRA’s MDPNP will lead to stifling of innovation for rare disease community.

The confirmatory study—which tracked 18 months of data—helped clear the way for new Alzheimer’s drug.

Newly-issued final guidance focuses on language used when communicating quantitative efficacy or risk information.

Service expected to help companies discover partners in funding.

Partnership to focus on developing immunotherapies for patients with cancer.

Here in New Jersey, our home base, summer is officially upon us, and the Canadian wildfire smoke has just cleared from the air. I’m sure the bird watchers would attest to the eager chirping as both wildlife and humans greedily enjoy the beautiful weather. But even as the seasons change, so does the technology that drives innovation, as coverage in the July issue of Pharmaceutical Executive® attests.

There are clear pathways that biopharma companies can take to sustain growth and remain competitive.

Complaints filed against CMS target the unconstitutionality of the Act, while the stifling of innovation in biopharma runs a parallel argument for numerous reasons